
Proceedings Paper
Non-invasive imaging of prostate cancer progression in nude mice using iRFP gene reporterFormat | Member Price | Non-Member Price |
---|---|---|
$17.00 | $21.00 |
Paper Abstract
Prostate cancer (PCa) is the second most common cancer in US men. Metastasis is the final step of tumor progression and remains the primary cause of PCa death. Hence preclinical, orthotopic models of PCa metastasis are necessary to develop new therapeutics against metastatic disease. Yet unlike irrelevant subcutaneous tumor models, the deployment of orthotopic models of cancer metastasis in drug research and development is limited by the inability to longitudinally monitor cancer progression/regression in response to administration of experimental pharmaceuticals. Recently, a nearinfrared fluorescent protein (iRFP) was created for deeper imaging [1]. Imaging prostate tumor growth and lymph node metastasis in nude mice therefore becomes possible using this new fluorescent gene reporter. In this study, we first developed an intensified CCD (ICCD)-based iRFP fluorescence imaging device. Then human PCa PC3 cell lines expressing iRFP gene reporter were orthotopically implanted in male Nu/Nu mice at 8-10 weeks old. After 6-10 weeks, in vivo, in situ and ex vivo fluorescence imaging was performed. In vivo iRFP fluorescence imaging showed that the detected fluorescence concentrated at the prostate and became stronger over time, indicating the growth of implanted PCa. Fluorescence was non-invasively detected at locations of prostate-draining lymph nodes as early as 5 weeks post implantation, indicating the metastasis to lymph nodes. In situ and ex vivo fluorescence imaging demonstrated that the detected signals from PCa and lymph nodes were correlated with cancer positive status of tissues as assessed through standard pathology.
Paper Details
Date Published: 8 March 2013
PDF: 6 pages
Proc. SPIE 8565, Photonic Therapeutics and Diagnostics IX, 85651E (8 March 2013); doi: 10.1117/12.2002092
Published in SPIE Proceedings Vol. 8565:
Photonic Therapeutics and Diagnostics IX
Andreas Mandelis; Brian Jet-Fei Wong; Anita Mahadevan-Jansen; Henry Hirschberg M.D.; Hyun Wook Kang; Nikiforos Kollias; Melissa J. Suter; Kenton W. Gregory M.D.; Guillermo J. Tearney M.D.; Stephen Lam; Bernard Choi; Steen J. Madsen; Bodo E. Knudsen M.D.; E. Duco Jansen; Justus F. Ilgner M.D.; Haishan Zeng; Matthew Brenner; Laura Marcu, Editor(s)
PDF: 6 pages
Proc. SPIE 8565, Photonic Therapeutics and Diagnostics IX, 85651E (8 March 2013); doi: 10.1117/12.2002092
Show Author Affiliations
Banghe Zhu, The Univ. of Texas Health Science Ctr. at Houston (United States)
Grace Wu, The Univ. of Texas Health Science Ctr. at Houston (United States)
Holly Robinson, The Univ. of Texas Health Science Ctr. at Houston (United States)
Grace Wu, The Univ. of Texas Health Science Ctr. at Houston (United States)
Holly Robinson, The Univ. of Texas Health Science Ctr. at Houston (United States)
Nathaniel Wilganowski, The Univ. of Texas Health Science Ctr. at Houston (United States)
Eva M. Sevick-Muraca, The Univ. of Texas Health Science Ctr. at Houston (United States)
Eva M. Sevick-Muraca, The Univ. of Texas Health Science Ctr. at Houston (United States)
Published in SPIE Proceedings Vol. 8565:
Photonic Therapeutics and Diagnostics IX
Andreas Mandelis; Brian Jet-Fei Wong; Anita Mahadevan-Jansen; Henry Hirschberg M.D.; Hyun Wook Kang; Nikiforos Kollias; Melissa J. Suter; Kenton W. Gregory M.D.; Guillermo J. Tearney M.D.; Stephen Lam; Bernard Choi; Steen J. Madsen; Bodo E. Knudsen M.D.; E. Duco Jansen; Justus F. Ilgner M.D.; Haishan Zeng; Matthew Brenner; Laura Marcu, Editor(s)
© SPIE. Terms of Use
